PATENT COOPERATION TREATY





INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of	of Transmittal of International Search Report
PN0273-PCT	ACTION (FORTIFICIALIZADE)	20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/NO 03/00444	29/12/2003	30/12/2002
Applicant		
AMERSHAM HEALTH AS		
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Auth ansmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists It is also accompanied by	of a total ofsheets. a copy of each prior art document cited in this	report.
Basis of the report		
 With regard to the language, the language in which it was filed, un 	international search was carried out on the bas less otherwise indicated under this item.	sis of the international application in the
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of the	he international application furnished to this
was carried out on the basis of th	e sequence listing :	ternational application, the international search
	onal application in written form.	
	ernational application in computer readable form	n.
	this Authority in written form. this Authority in computer readble form.	
the statement that the su	bsequently furnished written sequence listing d	oes not go beyond the disclosure in the
the statement that the inf	as filed has been furnished. ormation recorded in computer readable form is	s identical to the written sequence listing has been
furnished		,
2. X Certain claims were fou	nd unsearchable (See Box I).	
3. Unity of invention is lac	king (see Box II).	
4. With regard to the title,		
the text is approved as su	ubmitted by the applicant.	
\overline{X} the text has been establis	shed by this Authority to read as follows:	
	THE HEPARIN BINDING DOMIAN	OF VEGF AND VEGFR-2
5. With regard to the abstract,		
	ubmitted by the applicant.	
the text has been establis	shed, according to Rule 38.2(b), by this Authori e date of mailing of this international search rep	ty as it appears in Box III. The applicant may, port, submit comments to this Authority.
6. The figure of the drawings to be pub	lished with the abstract is Figure No.	-
as suggested by the app	licant.	X None of the figures.
because the applicant fai	led to suggest a figure.	
because this figure bette	r characterizes the invention.	

International application No. PCT/NO 03/00444

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: 10 because they relate to subject matter not required to be searched by this Authority, namely:
	see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.: 1, 3-10 (all partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
٠.	
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest
	No protest accompanied the payment of additional search fees.



Continuation of Box I.1

Claims Nos.: 10

Claim 10 relates to a method of treatment of the human or animal body by surgery or by therapy or diagnostic medhods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: 1, 3-10 (all partly)

The present claim 1 relates inter alia to a peptide comprising the amino acid sequence of formula I. The initial phase of the search for such peptides revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim is impossible.

In addition, present claim 1 relates to an extremely large number of possible peptides. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the peptides. It seems highly unlikely that all the possible peptides would actually bind the heparin binding domain of VEGF and VEGFR-2, as is the desired function according to the description. In the present case, the claim so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has mainly been focused on the peptides defined with formula II, the peptides according to claim 2 and the peptides actually manufactured in examples 1-3. The search has also been focused at the idea of peptides capable of binding the heparin binding domain of the VEGF and its receptor VEGFR-2.

Additional claims relating to the peptides according to claim 1 have been searched with the same limitations.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

receipt of the search report or during any Chapter II procedure.

page 2 of 2

International Application No PCT/NO 03/00444

A. CLASSIFICATION OF SUB IPC 7 C07K2/00 C07K14/71

CO7K7/06

C07K7/08

A61K4

//C07K14/475,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\label{eq:minimum documentation searched (classification system followed by classification symbols)} IPC \ 7 \ C07K \ A61K$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Χ	WO 01 52875 A (LUDWIG INST CANCER RES) 26 July 2001 (2001-07-26) abstract page 19, line 10 -page 20, line 30 page 26, line 1 - line 19; examples	1-10
X	WO 99 40947 A (ESHIMA DENNIS ;POLLAK ALFRED (CA); THORNBACK JOHN (CA); FAUCONNIER) 19 August 1999 (1999-08-19) abstract page 12, line 2 - line 13; examples 2,6 claims	1-10
	 -/	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.			
Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
 "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search 5 May 2004	Date of mailing of the international search report 0 3 JUN 2004			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer TERESE PERSSON /EÖ			

2

International Application No PCT/NO 03/00444

	ISIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
X	DATABASE HCAPLUS [Online] MILLENNIUM PHARMACEUTICALS, INC.: "Humanized anti mammalian CC-chemokine receptor 2 (CCR2) antibodies and uses in therapeutics, prophylaxis and diagnosis" retrieved from STN INTERNATIONAL Database accession no. 2001:582061 XP002279014 see sequence in the end, aa 60-68 abstract -& WO 01 57226 A (MILLENIUM PHARMACEUTICALS, INC.) 9 August 2001 (2001-08-09) the whole document	
x	WO 97 02479 A (UNIV YALE ;CAI XIAOHONG (US); GAREN ALAN (US)) 23 January 1997 (1997-01-23) sequence 48, aa 94-105	. 1
x	US 5 981 229 A (PEARCE BARBARA J ET AL) 9 November 1999 (1999-11-09) sequence 58, aa 127-135	1
x	WO 99 14321 A (INST MEDICAL W & E HALL; PUTHALAKATH HAMSA (AU); REILLY LORRAINE 0) 25 March 1999 (1999-03-25) sequence 6, aa 86-94	1
X	US 5 948 667 A (MOLONEY MAURICE M ET AL) 7 September 1999 (1999-09-07) sequence 2, aa 60-69	1.
X	WO 99 10498 A (HELENTJARIS TIMOTHY G; PIONEER HI BRED INT (US); WANG XUN (US); BO) 4 March 1999 (1999-03-04) sequence 11, aa 14-22	1
	EL-SHEIKH AMR ET AL: "A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium." CANCER RESEARCH, vol. 62, no. 23, 1 December 2002 (2002-12-01), pages 7118-7123, XP002279013 ISSN: 0008-5472 (ISSN print) the whole document	1-10
A	US 2002/114780 A1 (HAMILTON JOHN ET AL) 22 August 2002 (2002-08-22) page 3, column 1, paragraph 5	1-10
	- /	

International Application No PCT/NO 03/00444

C.(Continua	ISIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
P,X	WO 03 007689 A (HUBBELL JEFFREY A; SCHOENMAKERS RONALD (CH); ETH OF ZURICH (CH); U) 30 January 2003 (2003-01-30) abstract page 23, line 9 - line 14; examples 1,3 claims	1-10
P,X	WO 03 074005 A (POCHON SIBYLLE ;ARBOGAST CHRISTOPHE (FR); BUSSAT PHILIPPE (FR); BR) 12 September 2003 (2003-09-12) abstract page 102, line 10 - line 11; claims	1-10

Information on patent family members

International Application No PCT/NO 03/00444

		· · · · · · · · · · · · · · · · · · ·				
Patent documen cited in search rep		Publication date	:	Patent fam member(s)		Publication date
WO 0152875	Α	26-07-2001	AU	2955401	A	31-07-2001
	- •		EP	1248642		16-10-2002
			WO	0152875		26-07-2001
			ÜS	2002065218		30-05-2002
 WO 9940947	Α	19-08-1999	AU	757554	R2	 27-02-2003
WO 3340347	^	13-00-1333	AU	2406699		30-08-1999
			CA	2320339		19-08-1999
			WO	9940947		19-08-1999
		•	EP	1056773		06-12-2000
			US	2003194373		16-10-2003
UO 0157000		00 00 2001	AII			
WO 0157226	Α	09-08-2001	AU	3327701		14-08-2001
			CA	2399080		09-08-2001
			EP	1255844		13-11-2002
			JP	2003521927		22-07-2003
		•	WO	0157226		09-08-2001
			US	2002150576	A1	17-10-2002
WO 9702479	Α	23-01-1997	WO	9702479		23-01-1997
			US	6140470	A	31-10-2000
US 5981229	Α	09-11-1999	US	5928900	Α'	27-07-1999
	••	*	AU	709405		26-08-1999
•			ΑŬ	7680994		22-03-1995
	-		CA	2170726		09-03-1995
			EP	0721506		17-07-1996
	•		FI	960977		30-04-1996
			JP	9504686		13-05-1997
		•	NO	960839		19-04-1996
			NZ	273497		25-03-1998
			WO	9506732		09-03-1995
WO 9914321	A	25-03-1999	AU	752360	 R2	 19-09-2002
MO 3314361	^	23··03-1333	AU	9145798		05-04-1999
			WO	9914321		25-03-1999
			CA	2304124		25-03-1999
•			EP ·	1015578		05-07-2000
		•	JP	2001524301		04-12-200
US 5948667	Α	07-09-1999	US	6137032	Α	24-10-2000
WO 9910498	A	04-03-1999	AU	9117598	Δ	16-03-199
MO 3310430	A	O4-03-1333	BR	9815588		22-01-200
			CA	2301500		04-03-1999
			EP	1007690		14-06-200
			HU	0002477		28-10-200
			PL	339005		
						04-12-200
			TR	200000547		21-05-200
			WO	9910498		04-03-1999
			US	2003163839		28-08-200
US 2002114	780 A1	22-08-2002	CA	2327208	A1	30-05-200
	9 A	30-01-2003	· CA	2454418		30-01-200
WO 0300768	•					
WO 0300768	, ,		WO US	03007689 2003064410		30-01-200

information on patent family members

International Application No
PCT/NO 03/00444

Patent document cited in search report Publication date Patent fair member(s) Publication date

WO 03074005 A 12-09-2003 WO 03074005 A2 12-09-2003